Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer.

• DOI: 10.1200/jco.1997.15.1.199
• Publication Date: 2017-02-24T09:51:47Z
• Authors: G Cavaletti; G Bogliun; V Crespi; L Marzorati; A Zincone; M Marzola; S Rota; A Galli; P Tredici; G Tredici
• Keywords: Ototoxicity; Neurotoxicity

PURPOSE To compare the neurotoxicity and ototoxicity of combination cisplatin plus paclitaxel versus cyclophosphamide using extensive clinical instrumental evaluation. PATIENTS AND METHODS Forty-six 51 consecutive patients affected by-epithelial ovarian cancer seen in our institution between October 1994 August 1995 entered study. After randomization, they were assigned to receive 75 mg/m2 every 3 weeks associated with 750 (CC group, n = 22) or 175 over a 3-hour infusion (CP 24). Treatment was repeated six times 43 nine 25. Before treatment after three, six, courses chemotherapy, underwent neurologic otologic examinations. RESULTS Mild sensory impairment evident even only three both treatments signs symptoms more severe at end treatment. On grounds only, it possible demonstrate difference CC CP treatment, due involvement some pain thermal modalities. However, overall severity neuropathy similar. Audiometric parameters demonstrated negative outcome compared patients. different closely correlated this initial audiologic performance. CONCLUSION Up schedules are similar terms when evaluated during immediately With doses used study, these toxicities not dose-limiting. Our results suggest that most toxic effects observed cisplatin.